PDF(Pubmed)
Abstract：
BACKGROUND: Sarcopenia and obesity are two abnormal body composition phenotypes, and sarcopenic obesity (SO) is characterized by both low skeletal muscle mass (sarcopenia) and high adiposity (obesity). SO negatively influences the clinical status of patients with chronic obstructive pulmonary disease (COPD). However, the studies exploring the prevalence and clinical effects of SO in COPD patients are limited. Our study aimed to elucidate the prevalence and impact of SO on COPD patients.
METHODS: In this cross-sectional study, the pulmonary function, St. George\'s Respiratory Questionnaire, exercise tolerance, body composition, and serum levels of resistin and TNF-α were assessed in 198 COPD patients. The clinical value of serum resistin and TNF-α for predicting SO in patients with COPD was evaluated.
RESULTS: In the 198 patients with COPD, the prevalence rates of sarcopenia, obesity, and SO in COPD patients were 27.27%, 29.8%, and 9.6%, respectively. Patients with SO experienced more severe symptoms of dyspnea and worse health related quality of life. The expression of resistin increased in patients with SO compared to other patients. The AUC value of serum resistin level for predicting SO was 0.870 (95% CI: 0.799-0.940). BMI (OR: 1.474, 95% CI: 1.124-1.934) and resistin (OR: 1.001, 95% CI: 1.000-1.002) levels were independent risk factors of SO in patients with COPD in Multivariate analysis.
CONCLUSIONS: The prevalence rates of SO in COPD patients was 9.6%. COPD accompanied by SO is significantly associated with worse pulmonary function and poor physical performance. Serum resistin may be a potential adjunct for predicting SO in COPD patients.
METHODS: In this cross-sectional study, the pulmonary function, St. George\'s Respiratory Questionnaire, exercise tolerance, body composition, and serum levels of resistin and TNF-α were assessed in 198 COPD patients. The clinical value of serum resistin and TNF-α for predicting SO in patients with COPD was evaluated.
RESULTS: In the 198 patients with COPD, the prevalence rates of sarcopenia, obesity, and SO in COPD patients were 27.27%, 29.8%, and 9.6%, respectively. Patients with SO experienced more severe symptoms of dyspnea and worse health related quality of life. The expression of resistin increased in patients with SO compared to other patients. The AUC value of serum resistin level for predicting SO was 0.870 (95% CI: 0.799-0.940). BMI (OR: 1.474, 95% CI: 1.124-1.934) and resistin (OR: 1.001, 95% CI: 1.000-1.002) levels were independent risk factors of SO in patients with COPD in Multivariate analysis.
CONCLUSIONS: The prevalence rates of SO in COPD patients was 9.6%. COPD accompanied by SO is significantly associated with worse pulmonary function and poor physical performance. Serum resistin may be a potential adjunct for predicting SO in COPD patients.
摘要：
背景：肌肉减少症和肥胖是两种异常的身体成分表型，肌肉减少性肥胖（SO）的特征是骨骼肌质量低（肌肉减少症）和肥胖高（肥胖）。SO对慢性阻塞性肺疾病（COPD）患者的临床状况产生负面影响。然而,探讨SO在COPD患者中的患病率和临床效果的研究有限.我们的研究旨在阐明SO对COPD患者的患病率和影响。
方法：在这项横断面研究中，肺功能，圣乔治呼吸问卷，运动耐受力,身体成分,对198例COPD患者血清抵抗素和TNF-α水平进行了检测。评价血清抵抗素和TNF-α预测COPD患者SO的临床价值。
结果：在198例COPD患者中，肌肉减少症的患病率,肥胖，COPD患者中SO占27.27%，29.8%,9.6%，分别。患有SO的患者经历了更严重的呼吸困难症状和更差的健康相关生活质量。与其他患者相比，SO患者抵抗素的表达增加。血清抵抗素水平预测SO的AUC值为0.870（95％CI：0.799-0.940）。多因素分析中BMI(OR:1.474,95%CI:1.124~1.934)和抵抗素(OR:1.001,95%CI:1.000~1.002)水平是COPD患者SO的独立危险因素。
结论：COPD患者中SO的患病率为9.6%。伴有SO的COPD与肺功能较差和身体表现差显著相关。血清抵抗素可能是预测COPD患者SO的潜在辅助指标。
方法：在这项横断面研究中，肺功能，圣乔治呼吸问卷，运动耐受力,身体成分,对198例COPD患者血清抵抗素和TNF-α水平进行了检测。评价血清抵抗素和TNF-α预测COPD患者SO的临床价值。
结果：在198例COPD患者中，肌肉减少症的患病率,肥胖，COPD患者中SO占27.27%，29.8%,9.6%，分别。患有SO的患者经历了更严重的呼吸困难症状和更差的健康相关生活质量。与其他患者相比，SO患者抵抗素的表达增加。血清抵抗素水平预测SO的AUC值为0.870（95％CI：0.799-0.940）。多因素分析中BMI(OR:1.474,95%CI:1.124~1.934)和抵抗素(OR:1.001,95%CI:1.000~1.002)水平是COPD患者SO的独立危险因素。
结论：COPD患者中SO的患病率为9.6%。伴有SO的COPD与肺功能较差和身体表现差显著相关。血清抵抗素可能是预测COPD患者SO的潜在辅助指标。
